Zebrafish Neuroblastoma Models

Background Models Details Phenotypic Evaluation Key Applications Study Examples

Background

Neuroblastoma is an embryonal malignancy arising from neural crest-derived sympathetic nervous system precursors. It most commonly develops in the adrenal medulla or paraspinal sympathetic ganglia and represents one of the most frequent extracranial solid tumors in children. The disease shows broad clinical heterogeneity, ranging from spontaneous regression in infants to highly aggressive metastatic disease in older children. Key pathological and molecular features include impaired sympathoadrenal differentiation, MYCN amplification, ALK mutations, chromosomal copy number alterations, and metastatic spread to bone marrow, bone, liver, and lymph nodes. Clinical symptoms vary by tumor location and may include abdominal mass, pain, fever, weight loss, hypertension, bone pain, and neurological signs.

Current treatment strategies include surgery, chemotherapy, radiotherapy, autologous stem cell transplantation, anti-GD2 immunotherapy, retinoid-based differentiation therapy, and targeted approaches such as ALK inhibitors in selected patients. Despite intensive multimodal treatment, high-risk and relapsed neuroblastoma remain difficult to cure. Major research challenges include tumor heterogeneity, therapy resistance, metastatic progression, lineage plasticity, and limited predictive models for pediatric drug development. Zebrafish neuroblastoma models provide an efficient in vivo platform to study tumor initiation, metastatic behavior, oncogene cooperation, and therapeutic response in a vertebrate system.

Why Zebrafish?

Zebrafish support rapid in vivo assessment of pediatric tumor biology.
Transparent larvae enable real-time imaging of tumor growth and dissemination.
Transgenic models recapitulate MYCN-, ALK-, and LMO1-driven neuroblastoma biology.
Small size allows scalable drug efficacy and toxicity evaluation.

Available Zebrafish Disease Models

Validated zebrafish neuroblastoma models combine xenograft and transgenic approaches to investigate tumor initiation, metastatic dissemination, oncogene cooperation, and therapeutic response.

Model Name	Induction Method	Features
Neuroblastoma Cell Line Xenograft Model	Fluorescently labeled human neuroblastoma cell lines, such as SK-N-BE(2), IMR-32, or Kelly cells, are transplanted into zebrafish embryos or larvae.	Suitable for rapid assessment of tumor cell survival, proliferation, invasion, dissemination, and drug response. Compatible with live imaging and fluorescence-based quantification.
Patient-Derived Neuroblastoma Xenograft Model	Fresh or cultured patient-derived neuroblastoma cells are fluorescently labeled and implanted into zebrafish larvae.	Provides a patient-relevant platform for evaluating heterogeneous tumor behavior and early therapeutic response. Useful for translational and personalized screening workflows.
MYCN/ALK-Driven Transgenic Neuroblastoma Model	Human MYCN is expressed in sympathoadrenal lineage cells, commonly under the dopamine-β-hydroxylase promoter, with or without activated ALK variants.	Models neuroblastoma initiation and oncogene cooperation. Particularly useful for studying MYCN-amplified and ALK-mutant disease mechanisms and targeted therapy response.
MYCN/LMO1 Neuroblastoma Metastasis Model	MYCN and LMO1 are co-expressed in sympathoadrenal cells using transgenic zebrafish systems.	Supports investigation of aggressive neuroblastoma progression, invasion, and metastasis. Suitable for mechanism studies involving metastatic drivers and susceptibility genes.

Phenotypic Evaluation & Validation Assays

Drug Response and Safety

Reduction in tumor burden
Inhibition of dissemination or metastatic outgrowth
Larval survival and gross morphology
Basic toxicity readouts, including edema and developmental delay

Invasion and Metastasis

Migration distance from injection or primary tumor site
Number of disseminated tumor foci
Metastatic spread to distant anatomical regions

Differentiation and Tumor Biology

Sympathoadrenal marker expression
MYCN-, ALK-, or LMO1-associated pathway activity
Changes in proliferation or apoptosis

Tumor Growth

Tumor fluorescence area or intensity
Tumor cell expansion over time
Tumor growth inhibition after treatment

Key Applications

In vivo anti-neuroblastoma drug screening for chemotherapy, targeted agents, and combination therapies.
Evaluation of ALK inhibitors and resistance mechanisms in ALK-mutant or MYCN-driven models.
Metastasis and invasion studies using fluorescent tumor tracking in live zebrafish.
Mechanistic studies of oncogene cooperation, including MYCN, ALK, LMO1, NF1, and related pathways.
Patient-derived tumor response profiling to support translational pediatric oncology research.

Study Examples

This study generated zebrafish models co-expressing MYCN and LMO1 in sympathoadrenal cells to investigate the role of LMO1 in high-risk neuroblastoma. Co-expression of LMO1 with MYCN accelerated tumor initiation and promoted metastatic disease. The authors combined zebrafish modeling with genomic and functional analyses to show that LMO1 acts as an oncogenic driver and cooperates with MYCN in neuroblastoma progression. The work established a valuable model for studying metastatic neuroblastoma and genetic susceptibility mechanisms.

Fig. 1. Co-expression of LMO1 and MYCN Is Associated with an Earlier Onset and Increased Penetrance of Neuroblastoma (Zhu S, Zhang X, et al., 2017).

Accelerate Neuroblastoma Research with Zebrafish Models

Advance your neuroblastoma research with zebrafish models designed for in vivo tumor growth analysis, metastasis evaluation, oncogene-driven mechanism studies, and early drug efficacy testing.

Contact Our Scientists

Reference

Zhu S, Zhang X, et al. LMO1 synergizes with MYCN to promote neuroblastoma initiation and metastasis. Cancer Cell. 2017;32(3):310–323.e5.

For research use only. Not intended for any clinical use.